

Index

A

ACAT1, 15
ACT. *See* Adoptive cell transfer
Actin, 184
Acute phase response (APR), 246–247
Acute respiratory distress syndrome (ARDS), 24
ACVR2, 248
ADAMTS1, 55
Adoptive cell transfer (ACT), 164–165, 234
ADT. *See* Androgen deprivation therapy
Aging
 immune suppressive cells, 91–92
 immunosenescence, 89–91
 inflammation, 89, 92
 metastasis drivers
 extracellular matrix, 86–89
 fibroblasts, 82–86
 overview, 81–82
 senescence-associated secretory
 phenotype, 83–85
 muscle wasting, 252–254
AGO2, 181
AKT, 166, 230
AKT1, 164, 182
ALDH, 199, 201
ALIX, 187
ALK, 35, 215
ALL, 305, 308–309
AML, 162, 196, 309
AMPK, 149, 156
Androgen deprivation therapy (ADT), 48
Angiogenesis, zebrafish studies, 287–288
Angiopietin-2, 20
APR. *See* Acute phase response
ARDS. *See* Acute respiratory distress syndrome
ARG1, 128, 157
AXL
 dormancy mechanisms, 3
 therapeutic targeting, 5
AZD2014, 307

B

B7-1, 233
Biopsy. *See* Liquid biopsy
BMP4, 50
BMP7, 52
Bone metastasis

breast cancer, 48
dormancy, 52
early colonization, 52–54
evolutionary biology, 57
immune surveillance escape, 56–57
lung cancer, 48–49
mechanisms, 51
osteoblastic growth, 55
osteolytic growth, 54–55
osteomimicry, 55–56
prostate cancer, 48
seed preselection and premetastatic niche, 51–52
tropism determinants
 calcium, 50–51
 hypoxia, 50
 physicochemical properties, 49
 sinusoid structure, 49
 vasculature and niches, 49–50
BRAF, 34, 39, 85, 222
Brain metastasis
 adaptive immune response, 38–39
 barriers to entry, 217–219
 breast cancer, 216
 clinical features, 32–34
 diagnosis, 214
 dissemination
 blood–brain barrier, 219–220
 cerebrospinal fluid seeding, 220
 pachymeningeal seeding, 220
 extracellular matrix in outgrowth
 control, 37–38
 extracellular vesicles, 35–36
 lung cancer, 214–216
 management
 immunotherapy, 39–40, 221–222
 overview, 214
 radiation therapy, 214, 220
 resection, 220–221
 melanoma, 216–217
 neuroinflammation, 36–37
 overview, 31–32
 phenotype, 34–35
 prospects for study, 40–41
BRCA1, 281
BRCA2, 34
Breast cancer
 bone metastasis, 48
 brain metastasis, 216

Index

C

Cachexia. *See* Muscle wasting
CAF. *See* Cancer-associated fibroblast
Calcium, bone metastasis role, 50–51
Cancer stem cell (CSC)
 epithelial-to-mesenchymal plasticity
 computational modeling of networks, 202–205
 metastasis, 201–202
 overview, 200–201
 metastasis role evidence, 198–200
 overview, 195–198
 premetastasis studies, 14
Cancer-associated fibroblast (CAF), 51,
 183, 307
CAR-T cell therapy, 227, 231, 234
CaSR, 50
Cathepsin B, 125
Cathepsin S, 37, 125
CCL2, 158, 186
 bone metastasis, 54
 brain metastasis role, 36
 macrophage activation, 131
 premetastasis studies, 14–15, 18, 20–21, 23
 tumor immune microenvironment, 101, 108
CCL3, 131
CCL5, 15, 101, 131, 182
CCL9, 101
CCL22, 134, 159
CCR2, 18, 22, 108, 309
CCR8, 166
CD19, 235
CD24, 269
CD28, 159, 234
CD39, 183
CD44, 196–197
CD47, 107, 188, 265
CD73, 183
CD80, 230
CD86, 167, 230
CD137, 234
CH25H, 186
Circulating tumor cell (CTC)
 biology, 265
 clinical relevance, 265–266
 liquid biopsy, 264–265
 premetastasis studies, 14, 16
Circulating tumor DNA (CtDNA)
 biology, 267
 clinical relevance, 267
 liquid biopsy, 266–267
CKB, 75
Claudin-2, 75
CNTF, 248
COX, 73
CRP, 89
CSC. *See* Cancer stem cell

CSF1, 101, 125, 133, 230
CSF1-R, 36
CTC. *See* Circulating tumor cell
CtDNA. *See* Circulating tumor DNA
CTLA-4, 36, 39, 41, 111, 159, 222, 227, 233–234
CXCL1, 73, 85, 91, 133
CXCL2, 73, 85, 131
CXCL3, 101
CXCL5, 73, 131
CXCL7, 131
CXCL10, 20
CXCL12, 2, 18–24, 50–52, 66, 73, 102, 133, 159, 182
CXCR1, 18
CXCR2, 18, 73, 101, 134
CXCR4, 18, 50–52, 55, 73, 159, 199, 289

D

DAM12, 21
DC. *See* Dendritic cell
Dendritic cell (DC), 56, 90, 100, 107, 134–135,
 183, 188, 232, 306
DICER, 181
DKK1, 15, 53
Dormancy
 bone metastasis, 52
 cell niches, 2–3
 clinical significance in management, 5–6
 definition, 1–2
 entrance pathways, 3–4
 escape, 109–110
 history of study, 2
 intravital microscopy of plasticity, 305–306
 reactivation mechanisms, 4–5

E

EAE. *See* Experimental autoimmune
 encephalomyelitis
ECM. *See* Extracellular matrix
EGF, 16, 54, 125
EGFR, 49, 101, 215, 267, 270
EMAP II, 230
EMT. *See* Epithelial-to-mesenchymal transition
Endothelium, tumor interactions, 107–108
Ephrin-A1, 15, 21
Ephrin-A2, 21
Epithelial-to-mesenchymal transition (EMT)
 cancer stem cell epithelial-to-mesenchymal
 plasticity
 computational modeling of networks, 202–205
 metastasis, 201–202
 overview, 200–201
 immune microenvironment, 103–104
 invasion, 124–126
ERBB2, 34

- ET1, 55
ET2, 230
EV. *See* Extracellular vesicle
Experimental autoimmune encephalomyelitis (EAE),
217–218
Extracellular matrix (ECM)
aging and metastasis, 88–89
brain metastasis outgrowth control, 37–38
diversity across organs, 87–88
intravital microscopy of plasticity, 307
matrisome degradation in premetastasis, 20–21
metastasis overview, 86–87
remodeling in invasion, 104, 124
Extracellular vesicle (EV)
brain metastasis microenvironment, 35–36
clinical implications, 186–188, 269
exchange between cancer and stromal cells,
182–183
immunomodulation in tumors,
183–184
liquid biopsy, 267–269
overview, 177–179
premetastatic niche establishment, 184–186
secretion pattern in cancer, 179–182
transfer between subpopulations of cancer
cells, 182
vascular remodeling, 184
Extravasation
immune microenvironment, 108
zebrafish studies, 289–290
- F**
Factor XII, 24
FAK, 102, 109, 289
FAS, 162
FasL, 71, 73, 102
FATP2, 167
Fecal microbiota transplantation (FMT), 237
FGE, 55
FGF2, 182
FGF5, 55
Fibroblast
aging changes and metastasis, 82–86
cancer-associated fibroblast, 51, 183, 307
Fibronectin, 18
FLT1. *See* VEGFR1
FMT. *See* Fecal microbiota transplantation
FOX1, 75
FOXO1, 156, 245
FOXO3, 245
FOXO4, 245
Foxp3, 166
FPRL1, 24
FRAP. *See* Intravital microscopy
FRET. *See* Intravital microscopy
- G**
Gal-9, 227, 233
GCK, 160
G-CSE, 23, 158
GDF8, 248
GFAP, 36, 70
GHSR, 250
GITR, 166
Glg1, 53
GLI2, 54
GLUT1, 55, 150, 158
GM-CSE, 69, 101, 233
Gpr132, 102
GPRC6A, 254
GS, 157, 161
GSK3, 251
GSPT1, 269
- H**
HA, 88
HAPLN1, 86, 88
HBV, 232
Hepatic stellate cell (HSC),
metastatic niche, 70–71
Hepatocyte, metastatic niche, 71
HER2, 35, 38, 48, 232
HGF, 70–71, 180
HIF-1, 50, 101–102, 150, 156–157
Hippo, 183
HK2, 160
HMGB1, 15, 18, 68, 108
HMMR, 37
HPV, 232–233
HRAS, 181
HRG, 72
HSC. *See* Hepatic stellate cell
HSP70, 186
Hypoxia, bone metastasis promotion, 50
- I**
ICAM-1, 68, 74, 108, 220, 288
IDO, 153, 163
IFNAR1, 158
IFN γ , 23, 38, 69, 110, 128, 151, 162, 248
IGF-1, 51, 54, 72, 245–246, 252
IGFBP7, 85
IL-1, 91, 108, 151
IL-2, 159, 231
IL-4, 151
IL-6, 70, 72, 85, 92, 109, 183–184, 186, 248
IL-8, 23, 186
IL-10, 111, 128, 151, 159, 161, 230, 309
IL-12, 133
IL-13, 151

Index

- IL-17, 133, 156
IL-35, 133, 230
Immunotherapy
 adoptive cell transfer, 164–165, 234
 brain metastasis, 39–40, 221–222
 cancer vaccine, 231–233
 cytokine therapy, 231
 direct enhancement of T-cell immunity,
 235–236
 immune checkpoint blockade, 233–234
 inflammation prevention, 236
 microbiota, 236–237
 overview, 227–228
 premetastasis site formation prevention, 236
 prospects, 237
 tumor immune response
 elimination phase, 228
 equilibrium phase, 228
 escape phase, 230
 overview, 228–229
 tumor microenvironment and malignancy,
 230–231
Inflammation
 aging, 89, 92
 prevention, 236
Intravasation
 immune microenvironment, 104–105
 zebrafish studies, 288–289
Intravital microscopy (IVM)
 abdominal imaging window, 301
 bone, 301
 combination with other techniques, 301–302
 FRAP, 300
 FRET, 299–300
 near-infrared imaging, 298–299
 overview, 297–298
 plasticity of cancer cells
 dormancy, 305–306
 extracellular matrix and vasculature, 307
 immune landscape, 306–307
 invasion, 303–305
 overview, 302–303
 therapy response, 307–309
 prospects, 309–310
 second harmonic generation, 298
 third harmonic generation, 298
Invasion
 epithelial-to-mesenchymal transition, 124–126
 extracellular matrix remodeling, 104, 124
 intravital microscopy of plasticity, 303–305
IVM. *See* Intravital microscopy

J
JAG1, 202
JAK1, 233

K
KAI1, 52
Ki67, 126
KLF4, 20, 198
Klotho, 86
KRAS, 101, 181, 188, 230
Kupffer cell, metastatic niche, 69–70

L
LAG-3, 111, 227, 233
LAK. *See* Lymphokine-activated killer cell
LDH, 156
LIF, 248, 281
LIFT, 52
Liquid biopsy
 circulating tumor cells, 264–266
 circulating tumor DNA, 266–267
 extracellular vesicles, 267–269
 overview, 263–264
 tumor-educated platelets, 269–270
Liver metastasis
 architecture and hemodynamic flow, 64–65
 genetic programs, 74–75
 inflammatory cells
 lymphocytes, 74
 macrophages, 72–73
 neutrophils, 73–74
 niche
 metastatic niche, 68–74
 premetastatic niche, 66–68
 phases, 64
 resident cells, 68–72
 steps, 65–66
 tropism, 63–64
Liver sinusoidal endothelial cell (LSEC), 68–69
LOX, 15–16, 18, 20–21, 51, 70
LPS, 151–152
LRAT, 70
LSEC. *See* Liver sinusoidal endothelial cell
Lung cancer
 bone metastasis, 48–49
 brain metastasis, 214–216
Lymphokine-activated killer cell (LAK), therapy, 12

M
Macrophage. *See also* Metastasis-associated
 macrophage; Tumor-associated
 macrophage
 CCL2 activation, 131
 liver metastasis, 72–73
 metabolism in tumor microenvironment
 alternatively activated macrophages, 152
 circulating tumor cells, 162–163
 metastasis initiation, 161

- metastatic niche, 163–164
 - overview, 148, 151, 154–155
 - premetastatic niche, 160
 - proinflammatory macrophages, 151–152
 - therapeutic targeting, 166–167
 - tumor-associated macrophages, 156–157
 - MAFbx, 244–245, 253
 - MAM. *See* Metastasis-associated macrophage
 - MCP-1, 167, 186
 - MCT-1, 55
 - MD-2, 23
 - MDSC. *See* Myeloid-derived suppressor cell
 - MEF2, 50
 - MEK, 39
 - Melanoma, brain metastasis, 216–217
 - MER, dormancy mechanisms, 3
 - Mesenchymal–epithelial transition (MET), 133, 136, 196, 304
 - MET, 185–186
 - MET. *See* Mesenchymal–epithelial transition
 - Metastasis-associated macrophage (MAM), 71–72, 131, 133–134, 136
 - MHC, nonclassical signaling, 107
 - MICA, 105
 - MICB, 105
 - MicroRNA
 - bone metastasis, 55
 - brain metastasis, 34
 - immunomodulation by extracellular vesicles, 183–184
 - liver metastasis, 74
 - MIE, 68, 186
 - MMP1, 55
 - MMP2, 21, 125
 - MMP3, 20, 219
 - MMP8, 74, 130
 - MMP9, 21, 23, 70, 73–74, 108, 109, 125, 130, 134
 - MMP10, 20
 - MMP14, 21, 70
 - MRD, 267
 - MSK1, 52
 - MSP, 54
 - mTORC1, 149–150, 156
 - MULT1, 105
 - MuRF1, 244–245, 249–250, 253
 - MUSA1, 244
 - Muscle wasting
 - aging-related muscle wasting, 252–254
 - cachexia mechanisms, 244–249
 - overview, 243–244
 - prospect for study, 254–255
 - spectrum in cancer patients, 244–245
 - therapy-induced muscle wasting, 249–252
 - MYC, 34, 101, 182–183, 230
 - Myeloid-derived suppressor cell (MDSC), 19, 91, 158
 - MyoD, 245
- ## N
- NANOG, 198–199
 - Natural killer cell, avoidance, 105–106, 128
 - NDRG2, 73
 - NET. *See* Neutrophil extracellular trap
 - Neutrophil, liver metastasis role, 73–74
 - Neutrophil extracellular trap (NET)
 - liver metastasis, 74
 - omental homeostasis, 23–25
 - platelet aggregation stimulation, 128
 - therapeutic targeting, 236
 - tumor adhesion effects, 129–130
 - NFAT, 50, 165
 - NF- κ B. *See* Nuclear factor- κ B
 - NKG2D, 20, 105, 128
 - NOS, 73, 152
 - NOTCH, 183
 - NOX, 164
 - NOX4, 248
 - NP-1, 22
 - Nrf2, 152
 - NSAIDs, 236
 - nSMase2, 180, 184, 187
 - Nuclear factor- κ B (NF- κ B), 18, 20, 24, 164, 249–250
- ## O
- OCT4, 198–199
 - OPG, 54
 - OPN, 55, 281, 305–306
- ## P
- p21, 85
 - p38
 - dormancy mechanisms, 3
 - therapeutic targeting, 5
 - p53, 85
 - PAD4, 24
 - PAI-1, 83, 85
 - Parathyroid hormone (PTH), 54
 - PARP, 216
 - PCK1, 165
 - PD-1, 38, 156, 165–167, 183, 227, 233, 235–236, 309
 - PDGF, 55, 133, 270
 - PDGFR, 70
 - PDL-1, 36, 39, 41, 69, 102, 111, 167, 183, 227, 230, 233, 235–236
 - PD-L2, 134, 230
 - PDPK1, 184, 220
 - Pembrolizumab, 39
 - PER, 165
 - PFKB3, 151
 - Phagocytosis, avoidance, 107
 - PI3K, 36
 - PKM, 158

Index

- PKM2, 160
PPAR, 157
PPAR- γ , 161
Premetastasis
 extracellular matrix matrisome degradation, 20–21
 extracellular vesicles in niche establishment,
 184–186
 host-led activity, 22–23
 immunometabolism in niche
 CD8⁺ T cells, 158–159
 macrophages, 160
 overview, 157–158
 Tregs, 159–160
 liver metastasis, 66–67
 mouse model, 12–13
 neutrophil extracellular traps and omental
 homeostasis, 23–25
 niche
 elements, 18–20
 formation, 109
 organotropism, 21–22
 overview, 11–13
 Paget mechanism, 13–15
 site formation prevention, 236
 TLR4 ligands, 23
 tumor secretome, 15–18
 vascular permeability and osteolysis, 21
Prostate cancer, bone metastasis, 48
PSA, 55
PTEN, 35–36, 53, 156, 166, 186
PTH. *See* Parathyroid hormone
P2Y2, 158
- R**
- Rab22a, 180
Rab27a, 179
Rab27b, 179–180
RANKL, 159
 bone metastasis, 51, 54
 premetastasis studies, 15–16, 25
REDD1, 157, 161, 163
RELN, 38
RIG-I, 183
RYR1, 50, 248
- R**
- S100A4, 22
S100A8, 16, 19–23, 109
S100A9, 109
S1P1, 288
SAA1, 72
SAA2, 72
SAA3, 16, 18, 21, 23
Sarcopenia, 252–254
SASP. *See* Senescence-associated secretory phenotype
- SDF-1. *See* CXCL12
Sem3A, 22–23
Senescence-associated secretory phenotype (SASP),
 83–85
Septin-9, 267
SERCA, 165
SIN3A, 199
SIN3B, 85
SLC25 A1, 152
SNAI1, 198
SNAI2, 198
SNAIL, 101
SOX2, 34, 125, 198–199
SOX9, 34, 198–199
SPARC, 125
SPYLC2
SREBP, 150
STAT3, 72, 164, 248
SUCNR1, 151
SUM159, 202
- T**
- TAM. *See* Tumor-associated macrophage
TAN. *See* Tumor-associated neutrophil
T cell
 bone metastasis immune escape, 56
 cytotoxic T-cells
 aging, 92
 brain metastasis, 38
 direct enhancement of T-cell immunity, 235–236
 immunity evasion by tumors, 110–111, 146
 liver metastasis niche, 71, 74
 metabolism in tumor microenvironment
 CD8⁺ T cells, 149–150, 153
 circulating tumor cells, 162
 metastasis initiation, 160–161
 metastatic niche, 163
 overview, 147, 149, 154–155
 premetastatic niche
 CD8⁺ T cells, 158–159
 overview, 157–158
 Tregs, 159–160
 therapeutic targeting, 164–166
 Tregs, 150–151, 153, 156
 Tregs in aging, 91–92
TEP. *See* Tumor-educated platelet
TGF- β . *See* Transforming growth factor- β
Tie2, 305
TIGIT, 111
TIL. *See* Tumor-infiltrating lymphocyte
TIM3, 111, 227, 233
TIME. *See* Tumor immune microenvironment
TIMP1, 66, 71, 133
TLR4, 18, 23, 25, 109
TLR7, 68

- TMEM. *See* Tumor microenvironment for metastasis
TNFR1, 250
TNF- α . *See* Tumor necrosis factor- α
TPA, 83
TRAF6, 244
Transforming growth factor- β (TGF- β)
 bone metastasis, 54–55
 dormancy mechanisms, 3–4
 liver metastasis, 71
 muscle wasting, 248–249
 T-cell immunity enhancement, 235
 therapeutic targeting, 5
TRAP1, 164
TRBP, 181
TSC, 156
TSP-1, 52
Tumor-associated macrophage (TAM), 91, 125–126,
 133, 135, 288
Tumor-associated neutrophil (TAN), 124–126
Tumor-educated platelet (TEP), liquid biopsy, 269–270
Tumor immune microenvironment (TIME),
 establishment, 100–102
Tumor-infiltrating lymphocyte (TIL), 12, 235
Tumor microenvironment for metastasis (TMEM),
 126–127, 229–230, 305
Tumor necrosis factor- α (TNF- α)
 dormancy escape role, 109
 premetastasis studies, 15, 20, 23
TWIST, 124, 289
TYRO3
 dormancy mechanisms, 3
TYRP2, 186
- V**
VAP-1, 128
VCAM-1, 15, 53, 68, 108–109, 128, 133
VEGF, 55, 73, 126, 130, 180, 182, 184, 219, 287–290, 309
 liver metastasis, 66, 74
 premetastasis studies, 15–16, 18–19, 21, 23
 senescence-associated secretory phenotype, 84
VEGFR, 290
VEGFR1, 18, 109, 132–133
VLA-4, 186, 289
VSIG4, 167
- W**
WNT, 15, 302
- Z**
ZEB1, 124
Zebrafish models
 advantages in cancer research, 280–281
 cancer cell transplantation
 allografts, 285
 xenografts, 285–286
 genetic manipulation, 281, 283
 high-throughput chemical genetic screening,
 286–287
 life stages and development, 280
 metastasis studies
 angiogenesis, 287–288
 colonization at secondary site, 290
 intravasation and survival, 288–289
 local invasion, 287–288
 tumor cell homing and extravasation,
 289–290
 overview, 279–280
 transgenic lines and pigment mutants,
 283–285
ZIP14, 248–249
ZO-1, 34, 184, 217
ZO-2, 217
ZO-3, 217